PEDF as a treatment for cervical cancer.
Murray
Anne R
AR
Department of Physiology, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA.
Ma
Jian-xing
JX
D020533:Angiogenesis Inhibitors / Q000494:pharmacology / Q000627:therapeutic use*; D005136:Eye Proteins / Q000494:pharmacology / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D051795:Hypoxia-Inducible Factor 1, alpha Subunit / Q000378:metabolism; D009389:Neovascularization, Pathologic / Q000188:drug therapy*; D009414:Nerve Growth Factors / Q000494:pharmacology / Q000627:therapeutic use*; D015843:Serpins / Q000494:pharmacology / Q000627:therapeutic use*; D047368:Tumor Burden / Q000187:drug effects; D002583:Uterine Cervical Neoplasms / Q000098:blood supply / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D042461:Vascular Endothelial Growth Factor A / Q000378:metabolism; D000099174:Pigment Epithelium-Derived Factor
D020533:Angiogenesis Inhibitors; D005136:Eye Proteins; D051795:Hypoxia-Inducible Factor 1, alpha Subunit; D009414:Nerve Growth Factors; D015843:Serpins; D042461:Vascular Endothelial Growth Factor A; D000099174:Pigment Epithelium-Derived Factor